T and B Cell-based In Vivo Assay

Creative Biolabs offers in vivo assay service with premium quality to identify immunogenic epitopes using various animal models and cutting-edge analytical techniques.

Discover the Tumor-associated Peptides Presented in Vivo

As we all know, tumor antigens are processed by antigen presentation cells and then presented on major-histocompatibility-complex class I (MHC-I) molecules, also called the human leukocyte antigen (HLA) in humans. In cancer epitope studies, most methods used for peptide-MHC studies are limited to in vitro assays to analyze the proteome-level peptide library. However, the cancer epitopes have much association with the post-translation process and could not be predicted by the genome-scale analysis of mRNA. The crucial step of antigen presentation in vivo should not be neglected if you want to identify the cancer peptides.

Fig.1 Identification of cancer antigens in vivo using the PDX mouse models.¹

In Vivo Assay Services at Creative Biolabs

Our in vivo assay is dedicated to directly identifying T and B cell epitope peptides processed and presented by in vivo immune system. The advanced techniques for peptide purification and identification have provided us insight into the complex cancer epitopes.

Workflow

In Vivo Models Available

Multiple species of animal models are available for in vivo studies.
Various types of mouse models are used with high frequency, including transgenic mice and xenograft mouse models.

Types	Features	Functions
MHC-I Transgenic Mouse Model	Expressing the human HLA-A2 molecular	Investigating CD8+ T cell responsive antigenic epitope.
MHC-II Transgenic Mouse Model	Harboring the human HLA-DR molecular	Investigating CD4+ T cell responsive antigenic epitope.
Double Transgenic Mouse Model	Expressing MHC-I and MHC-II molecule	Monitoring the synergy function of CD8+ and CD4+ T cell responses.
Xenograft Model	Patient-derived tumor model	Providing a larger cancer antigen peptidome for screening.

Immunodominant Epitope Evaluation Services

Highlights of Our Services

Improved efficiency
Identify physiologically relevant cancer peptides
Animal models with more HLA types
Provide fewer but high-quality and reliable immunodominant epitope candidates
Comprehensively characterization of the tumor epitopes using multiple actions mechanism-related assays

Creative Biolabs has established advanced platforms to provide multiple approaches to provide an enlarged peptidome analysis of tumors and provide authentic tumor peptides for your targeted immunotherapy. For more information on the solutions of cancer antigen-related services, please contact us by e-mail.

Reference

Rijensky, N. M.; et al. Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse. Molecular & cellular proteomics: MCP. 2020, 19(8): 1360–1374.

For Research Use Only | Not For Clinical Use